The value of PSMA PET for risk stratification in prostate cancer: an update and future aspects
Authors:
Open Access
- 25 December 2025
- journal article
- review article
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 56 (2) , 229-234
Abstract
No abstract availableKeywords
Funding Information
- Innovative Health Initiative
- Prostate Cancer Foundation (22TACT01)
- Prostate Cancer Foundation (101172722)
- Prostate Cancer Foundation (101172788)
- AstraZeneca (95663957)
- Deutsche Forschungsgemeinschaft (FE1573/7-1 / 714209)
This publication has 39 references indexed in Scilit:
- Comparison of diagnostic performance between manual diagnosis following PROMISE V2 and aPROMISE utilizing Ga/F-PSMA PET/CTAnnals of Nuclear Medicine, 2025
- A visual whole-body tumor-burden classification based on PSMA PET/CT to predict response to novel androgen receptor signaling inhibitors for metastatic hormone-sensitive prostate cancer patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2025
- Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPCEuropean Journal of Nuclear Medicine and Molecular Imaging, 2025
- Discordance between prostate MRI and PSMA-PET/CT: the next big challenge for primary prostate tumor assessment?European Radiology, 2025
- PSMA PET/CT SUVmax as a prognostic biomarker in patients with metachronous metastatic hormone-sensitive prostate cancer (mHSPC)Clinical and Translational Oncology, 2024
- PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0European Journal of Nuclear Medicine and Molecular Imaging, 2023
- Adherence to a risk‐adapted screening strategy for prostate cancer: First results of the PROBASE trialInternational Journal of Cancer, 2022
- Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography–Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate CancerJAMA Network Open, 2021
- Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?Annals of Nuclear Medicine, 2021
- PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysisEuropean Journal of Nuclear Medicine and Molecular Imaging, 2020